US Penny Stocks To Watch In January 2025

As the S&P 500 reaches another record high, investors are keeping a close eye on market movements, driven by strong corporate earnings and recent policy announcements. While traditionally associated with higher risk, penny stocks—representing smaller or newer companies—can still present valuable opportunities for those willing to explore beyond the major indices. By focusing on firms with solid financial foundations and potential for growth, investors can uncover promising prospects among these often-overlooked stocks.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$110.92M	★★★★★★
BAB (OTCPK:BABB)	$0.87505	$6.41M	★★★★★★
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.87	$12M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.97	$2.09B	★★★★☆☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.2896	$11.03M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$3.12	$59.16M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.28	$22.17M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9272	$82.51M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.31	$361.98M	★★★★☆☆

Click here to see the full list of 710 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Senti Biosciences (NasdaqCM:SNTI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Senti Biosciences, Inc. is a preclinical biotechnology company focused on developing next-generation cell and gene therapies using its gene circuit platform technologies for various diseases, with a market cap of $20.51 million.

Operations: No revenue segments are reported for this preclinical biotechnology company.

Market Cap: $20.51M

Senti Biosciences, Inc., a pre-revenue biotechnology company with a market cap of US$20.51 million, is focused on developing innovative cell and gene therapies. Recent developments include the dosing of the first patient in a pilot trial for SN301A in collaboration with Celest Therapeutics and positive initial data from its SENTI-202 trial targeting hematologic malignancies. Despite no significant revenue streams, Senti has strengthened its financial position through private placements totaling nearly US$57.6 million. However, it faces challenges such as high volatility and limited cash runway despite being debt-free and having experienced board members guiding strategic decisions.

• Click here and access our complete financial health analysis report to understand the dynamics of Senti Biosciences.
• Assess Senti Biosciences' future earnings estimates with our detailed growth reports.

Village Farms International (NasdaqCM:VFF)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Village Farms International, Inc. operates in North America producing, marketing, and selling greenhouse-grown tomatoes, bell peppers, and cucumbers with a market cap of $86.18 million.

Operations: The company's revenue segments include $146.70 million from Canadian cannabis, $163.00 million from VF Fresh produce, and $17.84 million from U.S. cannabis operations.

Market Cap: $86.18M

Village Farms International, Inc., with a market cap of US$86.18 million, operates in the greenhouse produce and cannabis sectors. Recent earnings show an increase in sales to US$83.37 million for Q3 2024 but remain unprofitable with a net loss of US$0.82 million. The company has a satisfactory net debt to equity ratio of 6.5% and its short-term assets exceed both short- and long-term liabilities, indicating financial stability despite ongoing losses. While trading at good value compared to peers, profitability is not expected soon due to increased losses over five years and an inexperienced management team averaging 1.4 years tenure.

• Click here to discover the nuances of Village Farms International with our detailed analytical financial health report.
• Understand Village Farms International's earnings outlook by examining our growth report.

WidePoint (NYSEAM:WYY)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: WidePoint Corporation offers technology management as a service (TMaaS) to government and business enterprises in North America and Europe, with a market cap of $38.30 million.

Operations: The company's revenue is primarily generated from its Managed Mobility Solutions (MMS) segment, which accounted for $133.12 million.

Market Cap: $38.3M

WidePoint Corporation, with a market cap of US$38.30 million, is currently unprofitable but shows signs of potential through its Managed Mobility Solutions segment, generating US$133.12 million in revenue. Despite trading at 71.9% below estimated fair value and experiencing high share price volatility, it maintains financial stability with short-term assets exceeding liabilities and no debt burden. Recent developments include securing a new contract for Smart City IoT programs and reporting increased sales to US$34.62 million for Q3 2024 compared to the previous year, although net losses persist at US$0.43 million for the quarter.

• Get an in-depth perspective on WidePoint's performance by reading our balance sheet health report here.
• Gain insights into WidePoint's future direction by reviewing our growth report.

Summing It All Up

• Click here to access our complete index of 710 US Penny Stocks.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com